Topics

New drugs for non-alcoholic steatohepatitis and HIV infection: great expectations with a great absent?

07:00 EST 13th February 2020 | BioPortfolio

Summary of "New drugs for non-alcoholic steatohepatitis and HIV infection: great expectations with a great absent?"

In recent years, there has been an increasing number of clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). People living with HIV (PLWH) are commonly excluded from these studies, usually due to concerns over drug-drug interactions (DDI) associated with antiretroviral therapy (ART). The Steatohepatitis in HIV Emerging Research (SHIVER) Network, a group of international experts in hepatology and infectious diseases, discusses our current understanding on the interaction between HIV and NASH, and the issues related to the inclusion of PLWH in NASH clinical trials. Recent trials addressing NASH treatment in PLWH are discussed. The risk of DDI between ART and aramchol, cenicriviroc, elafibranor, obeticholic acid and resmetirom (MGL-3196), which are currently in phase III trials for the treatment of NASH, are reviewed. Finally, a model for trial design to include PLWH is proposed, strongly advocating for the scientific community to include this group as a sub-population within studies.

Affiliation

Journal Details

This article was published in the following journal.

Name: Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Pages:

Links

DeepDyve research library

PubMed Articles [15231 Associated PubMed Articles listed on BioPortfolio]

Letter to the Editor: Impact of non-alcoholic steatohepatitis on liver-related outcomes in chronic hepatitis B.

We read with great interest the article by Choi et al. reporting the impacts of concomitant non-alcoholic steatohepatitis (NASH) on the clinical outcomes and all-cause mortality in chronic hepatitis B...

γδT cells and CD1d, novel immune players in alcoholic and nonalcoholic steatohepatitis?

Alcoholic and non-alcoholic fatty liver diseases (NALFD) have emerged as the leading causes of chronic liver diseases worldwide, having a similar continuum of disorders ranging from simple steatosis t...

Plasma metabolic alterations in patients with severe obesity and non-alcoholic steatohepatitis.

Obesity can influence hepatic mitochondrial function, and cause non-alcoholic steatohepatitis (NASH). Diagnosis and follow-up rely on invasive liver biopsy so blood-based markers are urgently required...

MRI presentation of hepatocellular carcinoma in non-alcoholic steatohepatitis (NASH).

To describe the magnetic resonance imaging (MRI) features of hepatocellular carcinoma (HCC) in patients with non-alcoholic steatohepatitis (NASH).

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.

MSDC-0602K is a novel insulin sensitizer designed to preferentially target the mitochondrial pyruvate carrier while minimizing direct binding to the transcriptional factor PPARγ. Herein, we aimed to ...

Clinical Trials [8084 Associated Clinical Trials listed on BioPortfolio]

A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis

This study is intended to find out whether treatment with rosiglitazone improves the state of the liver and related blood markers in patients with nonalcoholic steatohepatitis (NASH).

Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis

The aim of this study is to evaluate the efficacy of metadoxine as a therapy for patients with biopsy-proven non-alcoholic steatohepatitis.

The Effect of HIT in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis

This pilot study aims to investigate whether 6 weeks of twice weekly High-intensity Interval Training (HIT) results in improvements in disease-specific measures, feelings of general well-b...

Digoxin for Patients With Non-alcoholic Steatohepatitis (NASH)

The purpose of this study is to assess if digoxin is safe and efficacious in treating patients with non-alcoholic steatohepatitis (NASH) within the approved target range of 0.7 to 1 ng/ml.

A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

The purpose of this sub-study of MB130-045 is to determine the pharmacokinetic effects, pharmacodynamic effects, efficacy and safety of BMS-986036 20 mg QD in subjects with Non-alcoholic S...

Medical and Biotech [MESH] Definitions

Cytoplasmic hyaline inclusions in HEPATOCYTES. They are associated with ALCOHOLIC STEATOHEPATITIS and non-alcoholic STEATOHEPATITIS, but are also present in benign and malignant hepatocellular neoplasms, and metabolic, toxic, and chronic cholestatic LIVER DISEASES.

The geographic area of the Great Lakes in general and when the specific state or states are not indicated. It usually includes Illinois, Indiana, Michigan, Minnesota, New York, Ohio, Pennsylvania, and Wisconsin.

A federation of seven states on the southeast portion of the Arabian peninsula: Abu Dhabi, Ajman, Dubai, Fujairah, Ras al-Khaimah, Sharjah and Umm al-Qaiwain. In 1820 a treaty of peace was concluded between Great Britain and native rulers. During the 19th century the rulers agreed to suppression of the slave trade and restriction of foreign relations to Great Britain. The Trucial Council was established in 1952 and defense treaties with Great Britain terminated. In 1971 an independent six-member federation was formed, with Ras al-Khaimah joining the federation in 1972. (From Webster's New Geographical Dictionary, 1988, p1250)

Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.

An ancient civilization, known as early as 2000 B.C. The Persian Empire was founded by Cyrus the Great (550-529 B.C.) and for 200 years, from 550 to 331 B.C., the Persians ruled the ancient world from India to Egypt. The territory west of India was called Persis by the Greeks who later called the entire empire Persia. In 331 B.C. the Persian wars against the Greeks ended disastrously under the counterattacks by Alexander the Great. The name Persia in modern times for the modern country was changed to Iran in 1935. (From Webster's New Geographical Dictionary, 1988, p546 & Asimov, Words on the Map, 1962, p176)

Quick Search


DeepDyve research library

Relevant Topic

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Searches Linking to this Article